TAT-N24穿膜融合多肽对HepG2细胞增殖的影响

Inhibition of cell-permeable TAT-N24 fusion peptide on proliferation of HepG2 cells in vitro

目的观察TAT-N24穿膜融合多肽对肝癌细胞增殖的抑制作用。方法用纯化的TAT-N24穿膜融合多肽处理HepG2细胞,使用流式细胞仪检测细胞周期;采用BrdU掺入法检测细胞DNA合成;采用Western Blot法检测细胞内相关蛋白的表达水平。结果空白组、对照多肽组和TAT-N24处理组细胞BrdU掺入阳性率分别为42.7±3.6%、38.2±2.8%和25.3±2.7%(P<0.05);G0/G1期细胞比例分别为52.6±4.7%、52.0±4.6%和68.6±4.7%(P<0.05);三组细胞AKT磷酸化水平无显著性差异。结论 TAT-N24穿膜融合多肽能有效阻滞肝癌HepG2细胞的细胞周期进程,抑制DNA合成。TAT-N24穿膜融合多肽有望被开发为有效的肿瘤分子靶向治疗药物。

Objective To investigate the anti-proliferation effects of cell-permeable TAT-N24 fusion peptide in hepatoma cell line.Methods HepG2 cells were treated with cell-permeable TAT-N24 fusion peptide.The cell cycle was analyzed by flow cytometry,the proliferation of the cells was assayed by BrdU incorporation and the expression of phosphorylated AKT was detected by Western blot.Results The incorporation rates of BrdU in blank,control and TAT-N24 group were 42.7±3.6%,38.2±2.8% and 25.3±2.7%（P0.05）,respectively;the percentages of G0/G1 phase cells were 52.6±4.7%,52.0±4.6% and 68.6±4.7%（P0.05）,respectively;the phosphorylation of AKT in the three groups was not significantly different.Conclusion Cell-permeable TAT-N24 fusion peptide effectively inhibites the DNA synthesis and induces cell cycle blocked at G0/G1 phase of HepG2 cells.